StockNews.AI
BBIO
StockNews.AI
16 hrs

BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025

1. BBIO to present ATTRibute-CM data at ESC Congress 2025. 2. Acoramidis shows reduced cardiovascular mortality in open-label extension study. 3. ePosters highlight improvements in biomarkers compared to placebo. 4. Adverse reactions with Acoramidis are mild and manageable. 5. ATTR-CM treatment has significant potential in genetic disease market.

5m saved
Insight
Article

FAQ

Why Bullish?

The positive results from the ATTRibute-CM study may enhance investor confidence, reminiscent of similar outcomes for other biopharmaceuticals that resulted in price surges.

How important is it?

The article represents significant clinical developments for BridgeBio; investor interest may rise, impacting stock behavior.

Why Short Term?

The upcoming presentations can lead to immediate market reaction, similar to prior events in the biotech sector that drove stock price movements.

Related Companies

VRTXALNYAMGN
August 25, 2025 07:30 ET  | Source: BridgeBio Pharma, Inc. PALO ALTO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire oral presentation on additional open-label extension data from ATTRibute-CM and two ePosters with ATTRibute-CM data at Month 30 will be shared at the European Society of Cardiology (ESC) Congress 2025, taking place in Madrid, Spain from August 29 - September 1, 2025. Oral Presentation Acoramidis Reduces Cardiovascular Mortality (CVM): Results at Month 42 from the ATTRibute-CM Open-label Extension (OLE) Study Presenter: Kevin Alexander, M.D., Stanford University School of Medicine, USADate: Saturday, August 30 at 1:15 pm CEST/7:15 am ET ePosters: Acoramidis-mediated Improvement in NT-proBNP at Month 30 Compared with Placebo in Patients with ATTR-CM: Results from the ATTRibute-CM StudyPresenter: Nitasha Sarswat, M.D. of UChicago Medicine, USADate: Sunday, August 31 at 4:15 pm CEST/10:15 am ET Acoramidis Has a Beneficial Effect Compared with Placebo on Change from Baseline in NAC ATTR Stage at Month 30 in Patients with ATTR-CM: Results from the ATTRibute-CM StudyPresenter: Julian Gillmore, M.D., Ph.D., University College London's Centre for Amyloidosis, UKDate: Saturday, August 29 at 3:15 pm CEST/9:15 am ET About Attruby™ (acoramidis) INDICATION Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. IMPORTANT SAFETY INFORMATION Adverse Reactions Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively). About BridgeBioBridgeBio Pharma (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, and YouTube. BridgeBio Media Contact: Bubba Murarka, Executive Vice President, Corporate Development contact@bridgebio.com   (650)-789-8220 BridgeBio Investor Contact: Chinmay Shukla, Senior Vice President, Strategic Finance ir@bridgebio.com

Related News